in this issue
Regions :: Western Europe :: Switzerland
Cambrex and Tillotts Pharma Sign Agreement for Mesalamine-Based Technology
1:20 AM MDT | July 7, 2011 | Deepti Ramesh
Cambrex (East Rutherford, NJ) says it has entered into a development and commercialization agreement with Tillotts Pharma (Rheinfelden, Switzerland), a subsidiary of Zeria Pharmaceutical (Tokyo), for a proprietary mesalamine-based (5-ASA) technology for use in the treatment of inflammatory bowel disease. The announcement “serves as a prime example of Cambrex's commitment to accelerating our customers' drug development processes by providing technology-added products and services and further underscores our goal to being a leading player in the development...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee